Cargando…

Hemoglobin and Clinical Outcomes in Hemodialysis: An Analysis of US Medicare Data From 2018 to 2020

RATIONALE & OBJECTIVE: Anemia management in patients treated with maintenance dialysis remains a challenge. We sought to update information in this area by evaluating the association between hemoglobin and various outcome and utilization measures using data-rich Medicare sources. STUDY DESIGN: O...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, Eric W., Wang, Dongyu, Kapke, Alissa, Pearson, Jeffrey, Turenne, Marc, Robinson, Bruce M., Huff, Edwin D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898731/
https://www.ncbi.nlm.nih.gov/pubmed/36748065
http://dx.doi.org/10.1016/j.xkme.2022.100578
_version_ 1784882490613170176
author Young, Eric W.
Wang, Dongyu
Kapke, Alissa
Pearson, Jeffrey
Turenne, Marc
Robinson, Bruce M.
Huff, Edwin D.
author_facet Young, Eric W.
Wang, Dongyu
Kapke, Alissa
Pearson, Jeffrey
Turenne, Marc
Robinson, Bruce M.
Huff, Edwin D.
author_sort Young, Eric W.
collection PubMed
description RATIONALE & OBJECTIVE: Anemia management in patients treated with maintenance dialysis remains a challenge. We sought to update information in this area by evaluating the association between hemoglobin and various outcome and utilization measures using data-rich Medicare sources. STUDY DESIGN: Observational cohort study using data from the Consolidated Renal Operations in a Web-enabled Network and Medicare claims. SETTING & PARTICIPANTS: We studied 371,250 prevalent patients treated with hemodialysis, covering 3,326,072 patient-months in 2019. EXPOSURE: Monthly patient hemoglobin concentrations. OUTCOMES: We examined several outcomes, including mortality, all-cause hospitalization, cause-specific hospitalization, and emergency department utilization in the month following the exposure measurement. ANALYTICAL APPROACH: For each monthly observation period, we calculated unadjusted and adjusted (for demographics and comorbid condition) hazard ratios using Cox regression. RESULTS: The hemoglobin concentration was <10.5 g/dL for 40% of observations. We found an inverse association between mortality and hemoglobin measured over a range from <9 g/dL (HR, 2.53; 95% CI, 2.45-2.61; P < 0.0001, reference = 10.5-11 g/dL) to 11-11.5 g/dL (HR, 0.92; 95% CI, 0.89-0.96; P < 0.0001). Mortality risk started to increase at hemoglobin levels >11.5 g/dL. All-cause hospitalization, cause-specific hospitalization (including cardiovascular, infection, and several subcategories including coronavirus disease 2019 hospitalization), and emergency department utilization were inversely associated with hemoglobin concentration, with risk reduction stabilizing at hemoglobin levels of approximately 11.5-12 g/dL and higher. LIMITATIONS: As with prior observational studies, the observed associations are not necessarily causal. CONCLUSIONS: In a large US hemodialysis population, there were better clinical outcomes at higher hemoglobin concentrations over short exposure and follow-up periods, consistent with other observational studies that generally used longer exposure and follow-up times. Mortality risk increased at hemoglobin concentrations >11.5 g/dL, consistent with findings from erythropoiesis-stimulating agent clinical trials. The apparently beneficial short-term effects associated with higher hemoglobin concentrations suggest that hemoglobin measurements capture unmeasured elements of patient risk.
format Online
Article
Text
id pubmed-9898731
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-98987312023-02-05 Hemoglobin and Clinical Outcomes in Hemodialysis: An Analysis of US Medicare Data From 2018 to 2020 Young, Eric W. Wang, Dongyu Kapke, Alissa Pearson, Jeffrey Turenne, Marc Robinson, Bruce M. Huff, Edwin D. Kidney Med Original Research RATIONALE & OBJECTIVE: Anemia management in patients treated with maintenance dialysis remains a challenge. We sought to update information in this area by evaluating the association between hemoglobin and various outcome and utilization measures using data-rich Medicare sources. STUDY DESIGN: Observational cohort study using data from the Consolidated Renal Operations in a Web-enabled Network and Medicare claims. SETTING & PARTICIPANTS: We studied 371,250 prevalent patients treated with hemodialysis, covering 3,326,072 patient-months in 2019. EXPOSURE: Monthly patient hemoglobin concentrations. OUTCOMES: We examined several outcomes, including mortality, all-cause hospitalization, cause-specific hospitalization, and emergency department utilization in the month following the exposure measurement. ANALYTICAL APPROACH: For each monthly observation period, we calculated unadjusted and adjusted (for demographics and comorbid condition) hazard ratios using Cox regression. RESULTS: The hemoglobin concentration was <10.5 g/dL for 40% of observations. We found an inverse association between mortality and hemoglobin measured over a range from <9 g/dL (HR, 2.53; 95% CI, 2.45-2.61; P < 0.0001, reference = 10.5-11 g/dL) to 11-11.5 g/dL (HR, 0.92; 95% CI, 0.89-0.96; P < 0.0001). Mortality risk started to increase at hemoglobin levels >11.5 g/dL. All-cause hospitalization, cause-specific hospitalization (including cardiovascular, infection, and several subcategories including coronavirus disease 2019 hospitalization), and emergency department utilization were inversely associated with hemoglobin concentration, with risk reduction stabilizing at hemoglobin levels of approximately 11.5-12 g/dL and higher. LIMITATIONS: As with prior observational studies, the observed associations are not necessarily causal. CONCLUSIONS: In a large US hemodialysis population, there were better clinical outcomes at higher hemoglobin concentrations over short exposure and follow-up periods, consistent with other observational studies that generally used longer exposure and follow-up times. Mortality risk increased at hemoglobin concentrations >11.5 g/dL, consistent with findings from erythropoiesis-stimulating agent clinical trials. The apparently beneficial short-term effects associated with higher hemoglobin concentrations suggest that hemoglobin measurements capture unmeasured elements of patient risk. Elsevier 2022-12-07 /pmc/articles/PMC9898731/ /pubmed/36748065 http://dx.doi.org/10.1016/j.xkme.2022.100578 Text en © 2022 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Young, Eric W.
Wang, Dongyu
Kapke, Alissa
Pearson, Jeffrey
Turenne, Marc
Robinson, Bruce M.
Huff, Edwin D.
Hemoglobin and Clinical Outcomes in Hemodialysis: An Analysis of US Medicare Data From 2018 to 2020
title Hemoglobin and Clinical Outcomes in Hemodialysis: An Analysis of US Medicare Data From 2018 to 2020
title_full Hemoglobin and Clinical Outcomes in Hemodialysis: An Analysis of US Medicare Data From 2018 to 2020
title_fullStr Hemoglobin and Clinical Outcomes in Hemodialysis: An Analysis of US Medicare Data From 2018 to 2020
title_full_unstemmed Hemoglobin and Clinical Outcomes in Hemodialysis: An Analysis of US Medicare Data From 2018 to 2020
title_short Hemoglobin and Clinical Outcomes in Hemodialysis: An Analysis of US Medicare Data From 2018 to 2020
title_sort hemoglobin and clinical outcomes in hemodialysis: an analysis of us medicare data from 2018 to 2020
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898731/
https://www.ncbi.nlm.nih.gov/pubmed/36748065
http://dx.doi.org/10.1016/j.xkme.2022.100578
work_keys_str_mv AT youngericw hemoglobinandclinicaloutcomesinhemodialysisananalysisofusmedicaredatafrom2018to2020
AT wangdongyu hemoglobinandclinicaloutcomesinhemodialysisananalysisofusmedicaredatafrom2018to2020
AT kapkealissa hemoglobinandclinicaloutcomesinhemodialysisananalysisofusmedicaredatafrom2018to2020
AT pearsonjeffrey hemoglobinandclinicaloutcomesinhemodialysisananalysisofusmedicaredatafrom2018to2020
AT turennemarc hemoglobinandclinicaloutcomesinhemodialysisananalysisofusmedicaredatafrom2018to2020
AT robinsonbrucem hemoglobinandclinicaloutcomesinhemodialysisananalysisofusmedicaredatafrom2018to2020
AT huffedwind hemoglobinandclinicaloutcomesinhemodialysisananalysisofusmedicaredatafrom2018to2020